Ultragenyx Pharmaceutical Inc. (RARE) Social Stream
Ultragenyx Pharmaceutical Inc (RARE) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RARE.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-05 | 16 | $185 | $73 | $146.2 | $78.15 | 87.08% |
| 2022-01-11 | 16 | $185 | $73 | $143.933 | $78.15 | 84.18% |
| 2022-01-25 | 16 | $185 | $73 | $143 | $78.15 | 82.98% |
| 2022-01-26 | 16 | $185 | $73 | $142.4 | $78.15 | 82.21% |
| 2022-01-31 | 16 | $185 | $73 | $140 | $78.15 | 79.14% |
| 2022-02-11 | 16 | $185 | $73 | $140 | $78.15 | 79.14% |
| 2022-02-14 | 15 | $185 | $73 | $139.466 | $78.15 | 78.46% |
| 2022-02-16 | 15 | $186 | $73 | $139.533 | $78.15 | 78.55% |
The Trend in the Analyst Price Target
RARE's average price target has moved down $17.71 over the prior 48 weeks.
RARE reports an average of 70.55% for its upside potential over the past 45 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-04-19 | 17 | 195 | 80 | 154.880 | 105.39 | 46.96% |
| 2021-11-04 | 16 | 185 | 73 | 146.200 | 85.74 | 70.52% |
| 2022-01-11 | 16 | 185 | 73 | 143.933 | 72.76 | 97.82% |
| 2022-01-31 | 16 | 185 | 73 | 140.000 | 69.93 | 100.2% |
| 2022-02-14 | 15 | 185 | 73 | 139.466 | 71.25 | 95.74% |
RARE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.57 | 11 | 1 | 2 | 1 | 1 | 15 |
The Trend in the Broker Recommendations
Over the past 18 months, RARE's average broker recommendation rating worsened by 0.1.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, Ultragenyx Pharmaceutical Inc's number of analysts covering the stock is higher than 616.16% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Ultragenyx Pharmaceutical Inc's average analyst price target is greater than 630.19% of them.
- In terms of how Ultragenyx Pharmaceutical Inc fares relative to stocks in the large market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 620.7% of that group.
- In the context of stocks in the large market cap category, Ultragenyx Pharmaceutical Inc's variance in analysts' estimates is lower than -511.34% of them.
In the Pharmaceutical Products industry, PRGO, NKTR, and MRVI are the three stocks most similar to Ultragenyx Pharmaceutical Inc regarding the price target and analyst recommendation information presented here.
Is RARE a Buy, Hold or Sell? See the POWR Ratings now!